Serge Belanger, an analyst from Needham, maintained the Buy rating on Collegium Pharmaceutical. The associated price target remains the same with $46.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Serge Belanger has given his Buy rating due to a combination of factors that highlight the potential of Collegium Pharmaceutical. The company’s upcoming earnings report for the third quarter of 2025 is anticipated to provide insights into its financial and operational performance, particularly regarding the sales trends of its key products like Jornay PM, Xtampza ER, and Belbuca. These updates are crucial as they reflect the company’s ability to maintain and expand its market presence.
Belanger’s confidence in Collegium Pharmaceutical is further bolstered by the company’s valuation, which he believes does not fully capture its growth prospects, profitability, and the enduring value of its assets. Additionally, the company’s successful history of acquiring and integrating new products into its portfolio supports the Buy rating, as it demonstrates a strategic approach to enhancing its product offerings and sustaining long-term growth.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of COLL in relation to earlier this year.